Provided by Tiger Trade Technology Pte. Ltd.

Aquestive Therapeutics Inc.

4.21
+0.33008.51%
Post-market: 4.20-0.0101-0.24%19:47 EDT
Volume:1.84M
Turnover:7.59M
Market Cap:513.63M
PE:-5.37
High:4.22
Open:3.91
Low:3.91
Close:3.88
52wk High:7.55
52wk Low:2.12
Shares:122.00M
Float Shares:115.00M
Volume Ratio:0.93
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7836
EPS(LYR):-0.7836
ROE:148.50%
ROA:-33.92%
PB:-15.26
PE(LYR):-5.37

Loading ...

NASD Most Active Issues

Dow Jones
·
Jan 13

Aquestive Therapeutics Inc : Leerink Partners Cuts Target Price to $7 From $11

THOMSON REUTERS
·
Jan 12

Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies in Anaphylm Filing - What's Changed

Simply Wall St.
·
Jan 12

Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet

Benzinga_recent_news
·
Jan 10

Aquestive Therapeutics Down Over 38%, on Track for Record Percent Decrease -- Data Talk

Dow Jones
·
Jan 10

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

Benzinga
·
Jan 10

Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application

Benzinga_recent_news
·
Jan 10

ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James

TIPRANKS
·
Jan 09

Aquestive Therapeutics Shares Plunge 37.2% After FDA Identifies Deficiencies in Marketing Application for Experimental Drug for Allergic Reactions

THOMSON REUTERS
·
Jan 09

BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, home lenders, First Solar

Reuters
·
Jan 09

Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)

TIPRANKS
·
Jan 09

BUZZ-Aquestive Therapeutics falls as FDA flags issues with oral allergy drug

Reuters
·
Jan 09

Aquestive Therapeutics Shares Down 48% Premarket After FDA Identifies Deficiencies in Co's Marketing Application for Its Experimental Drug for Allergic Reactions

THOMSON REUTERS
·
Jan 09

FDA Identifies Deficiencies in Aquestive Anaphylm Review, Approval Pending

Reuters
·
Jan 09

Aquestive Therapeutics Expands Global Regulatory Efforts for Anaphylm

Reuters
·
Jan 09

Aquestive Therapeutics Inc - Progresses Global Regulatory Expansion for Anaphylm

THOMSON REUTERS
·
Jan 09

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (Dibutepinephrine) Sublingual Film and Provides Business Update

THOMSON REUTERS
·
Jan 09

Aquestive Therapeutics Inc - FDA Identifies Deficiencies in Anaphylm Nda

THOMSON REUTERS
·
Jan 09

Aquestive Therapeutics Inc - FDA Review of Anaphylm Nda Ongoing

THOMSON REUTERS
·
Jan 09

Needle‑Free Anaphylaxis Treatments Poised for Growth: Physician Survey Supports Buy Rating on Aquestive’s Anaphylm (AQST)

TIPRANKS
·
Jan 09